Edition:
United States

CytomX Therapeutics Inc (CTMX.OQ)

CTMX.OQ on NASDAQ Stock Exchange Global Select Market

27.85USD
16 Feb 2018
Change (% chg)

-- (--)
Prev Close
$27.85
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
139,916
52-wk High
$28.96
52-wk Low
$11.40

Chart for

About

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development... (more)

Overall

Beta: --
Market Cap(Mil.): $1,069.68
Shares Outstanding(Mil.): 38.41
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 178.11 17.27
EPS (TTM): -- -- --
ROI: -- -1.15 35.43
ROE: -- -20.84 17.10

BRIEF-Perceptive Advisors LLC Reports 5.6 Pct Passive Stake In CytomX Therapeutics As On Dec 8

* PERCEPTIVE ADVISORS LLC REPORTS 5.6 PERCENT PASSIVE STAKE IN CYTOMX THERAPEUTICS INC AS ON DEC 8 - SEC FILING Source text (http://bit.ly/2BGceJ2) Further company coverage:

Dec 18 2017

BRIEF-Cytomx Therapeutics Says FDA Accepts IND For CTLA-4 Probody Therapeutic

* CYTOMX THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR CTLA-4 PROBODY THERAPEUTIC

Nov 28 2017

BRIEF-CytomX reports Q3 loss per share $‍0.28​

* CytomX announces third quarter 2017 financial results and operational progress

Nov 07 2017

BRIEF-CytomX Therapeutics appoints Charles Fuchs to board of directors

* CytomX Therapeutics Inc appoints Charles S. Fuchs, M.D., MPH to board of directors Source text for Eikon: Further company coverage:

Oct 24 2017

Competitors

  Price Chg
AstraZeneca plc (AZN.L) 4,740.50 +28.00
GlaxoSmithKline plc (GSK.L) 1,313.20 +4.60
Merck & Co., Inc. (MRK.N) $56.29 +0.30
Novartis AG (NOVN.S) CHF79.88 +0.20
Pfizer Inc. (PFE.N) $36.26 +0.55
Roche Holding Ltd. (ROG.S) CHF223.35 +0.20
Roche Holding Ltd. (RO.S) CHF226.60 +0.60
Sanofi SA (SASY.PA) €64.38 +0.08
ImmunoGen, Inc. (IMGN.OQ) $11.27 --
Seattle Genetics, Inc. (SGEN.OQ) $54.48 --

Earnings vs. Estimates